-
公开(公告)号：US20240084301A1
公开(公告)日：2024-03-14
申请号：US18357495
申请日：2023-07-24
Applicant: AMGEN INC.
Inventor： Elizabeth Ann KILLION , Jerry Ryan HOLDER , Bryan MEADE , Justin K. MURRAY , Oliver R. HOMANN , Briana Renee GRIEGO , Murielle Marie VENIANT ELLISON
IPC: C12N15/113 , A61P1/16 , A61P3/04
CPC classification number: C12N15/113 , A61P1/16 , A61P3/04 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322
Abstract: The present application relates to compositions and methods for modulating expression of Family with Sequence Similarity 13 Member A (FAM13A) protein. In particular, the present application relates to nucleic acid-based therapeutics for reducing FAM13A gene expression via RNA interference and methods of using such nucleic acid-based therapeutics to reduce abdominal adiposity, reduce body weight, reduce fat mass, improve metabolic parameters including insulin resistance and non-alcoholic steatohepatitis (NASH), and reduce risk of myocardial infarction.
-
公开(公告)号：US20170107255A1
公开(公告)日：2017-04-20
申请号：US15317911
申请日：2015-06-10
Applicant: AMGEN INC.
Inventor： Jerry Ryan HOLDER , Gayathri SWAMINATH , Michael J. FROHN , Brian Alan LANMAN , Anthony B. REED , Leslie P. Miranda , John G. Allen , Alexander J. Pickrell , Aaron C. Siegmund , Lewis D. Pennington , Bryant Yang
CPC classification number: C07K7/08 , A61K38/00 , A61K38/10 , A61K47/542 , A61K47/60 , C07K14/47 , C07K2319/30
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
-
公开(公告)号：US20160067347A1
公开(公告)日：2016-03-10
申请号：US14654501
申请日：2013-12-17
Applicant: AMGEN INC.
Inventor： Jerry Ryan HOLDER , Gayathri SWAMINATH , Leslie P. MIRANDA , Jennifer ARAL , Elizabeth M. DOHERTY , Thomas NIXEY
CPC classification number: A61K47/48215 , A61K38/08 , A61K38/10 , A61K47/60 , A61K47/6811 , C07K7/08 , C07K14/47 , C07K14/503
Abstract: The application is directed to APJ receptor agonist analogs having increased stability relative to the wild type apelin-13 and methods of using the agonist analogs. The analogs can be used, inter alia, in cardiac disorders such as heart failure.
Abstract translation: 该应用涉及相对于野生型apelin-13具有增加的稳定性的APJ受体激动剂类似物和使用激动剂类似物的方法。 类似物尤其可用于心脏病，例如心力衰竭。
-
公开(公告)号：US20250121056A1
公开(公告)日：2025-04-17
申请号：US18982197
申请日：2024-12-16
Applicant: AMGEN INC.
Inventor： Yuan CHENG , Chawita NETIROJJANAKUL , Jerry Ryan HOLDER , Bin WU , James R. FALSEY , Bradley J. HERBERICH , Kelvin SHAM , Leslie P. MIRANDA , Shu-Chen LU , Murielle M. VENIANT-ELLISON , Shanaka STANISLAUS , Junming YIE , Jing XU
IPC: A61K39/395 , A61K47/68 , A61P3/10 , C07K16/28
Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
-
公开(公告)号：US20210154318A1
公开(公告)日：2021-05-27
申请号：US17151045
申请日：2021-01-15
Applicant: Amgen Inc.
Inventor： Yuan CHENG , Chawita NETIROJJANAKUL , Jerry Ryan HOLDER , Bin WU , James R. FALSEY , Bradley J. HERBERICH , Kelvin SHAM , Leslie P. MIRANDA , Shu-Chen LU , Murielle VENIENT-ELLISON , Shanaka STANISLAUS , Junming YIE , Jing XU
IPC: A61K47/68 , A61P3/10 , C07K16/28 , A61K39/395
Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
-
Patent Agency Ranking
公开(公告)号：US20150023988A1
公开(公告)日：2015-01-22
申请号：US14207445
申请日：2014-03-12
Applicant: AMGEN INC.
Inventor： Justin K. MURRAY , Jerry Ryan HOLDER , Malgorzata WANSKA , Christopher M. TEGLEY , James R. FALSEY , Elizabeth M. DOHERTY , Leslie P. MIRANDA
IPC: A61K47/48 , C07K16/00 , A61K38/17 , C07K14/435
CPC classification number: A61K47/48438 , A61K38/00 , A61K47/60 , A61K47/68 , A61K47/6817 , C07K14/43518 , C07K14/705 , C07K16/44
Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
Abstract translation: 公开了包含分离的多肽的物质组合物，其是外周限制的Nav1.7抑制剂。 在一些公开的实施方案中，分离的多肽是Nav1.7的抑制剂。 其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。 公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。 还公开了治疗或预防疼痛的方法。
-
公开(公告)号：US20240327461A1
公开(公告)日：2024-10-03
申请号：US18497081
申请日：2024-06-11
Applicant: AMGEN INC.
Inventor： Jerry Ryan HOLDER , Gayathri SWAMINATH , Michael J. FROHN , Brian Alan LANMAN , Anthony B. REED , Leslie P. MIRANDA , John Gordon ALLEN , Alexander J. PICKRELL , Aaron C. SIEGMUND , Lewis D. PENNINGTON , Bryant YANG
CPC classification number: C07K7/08 , A61K38/10 , A61K47/542 , A61K47/60 , C07K14/47 , A61K38/00 , C07K2319/30
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
-
公开(公告)号：US20210261619A1
公开(公告)日：2021-08-26
申请号：US17160819
申请日：2021-01-28
Applicant: AMGEN INC.
Inventor： Jerry Ryan HOLDER , Gayathri SWAMINATH , Michael J. FROHN , Brian Alan LANMAN , Anthony B. REED , Leslie P. MIRANDA , John Gordon ALLEN , Alexander J. PICKRELL , Aaron C. SIEGMUND , Lewis D. PENNINGTON , Bryant YANG
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
-
公开(公告)号：US20180311372A1
公开(公告)日：2018-11-01
申请号：US15872841
申请日：2018-01-16
Applicant: AMGEN INC.
Inventor： Yuan CHENG , Chawita NETIROJJANAKUL , Jerry Ryan HOLDER , Bin WU , James R. FALSEY , Bradley J. HERBERICH , Kelvin SHAM , Leslie P. MIRANDA , Shu-Chen LU , Murielle VENIANT-ELLISON , Shanaka STANISLAUS , Junming YIE , Jing XU
CPC classification number: C07K16/28 , A61K39/395 , A61P3/10
Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
-
公开(公告)号：US20160024159A1
公开(公告)日：2016-01-28
申请号：US14773756
申请日：2014-03-12
Applicant: AMGEN INC
Inventor： Justin K. MURRAY , Jerry Ryan HOLDER , Malgorzata WANSKA , Christopher M. TEGLEY , James R. FALSEY , Elizabeth M. DOHERTY , Leslie P. MIRANDA , Kaustav BISWAS , Bin WU , Kelvin SHAM , Jason C. LONG
IPC: C07K14/435 , A61K38/17 , A61K47/48
CPC classification number: C07K14/43518 , A61K38/00 , A61K38/16 , A61K38/1709 , A61K38/1767 , A61K47/643 , A61K47/6817 , C07K14/435 , C07K14/46 , C07K14/47
Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
Abstract translation: 公开了包含分离的多肽的物质组合物，其是外周受限制的NaV1.7抑制剂。 在一些公开的实施方案中，分离的多肽是NaV1.7的抑制剂。 其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。 公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。 还公开了治疗或预防疼痛的方法。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.037 seconds)
